{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:57Z","timestamp":1792593657612,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58936-7","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:06:19Z","timestamp":1782133579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of mesenchymal stromal cells derived from the Wharton\u2019s jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assay"],"prefix":"10.1038","volume":"16","author":[{"given":"Silvia","family":"Torrents","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda-Buend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Codinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Marsal Ricom\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"del Trabazo del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edaz de Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosario","family":"P\u00e9rez-Torres Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"L\u00f3pez Torija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"L\u00f3pez Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pe\u00f1a Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Castillo-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Vives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"9674","key":"58936_CR1","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara, J. L., Levine, J. E., Reddy, P. & Holler, E. Graft-versus-host disease. Lancet 373 (9674), 1550\u20131561 (2009). PubMed PMID: 19282026. Pubmed Central PMCID: 2735047.","journal-title":"Lancet"},{"issue":"10","key":"58936_CR2","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","volume":"109","author":"HJ Deeg","year":"2007","unstructured":"Deeg, H. J. How I treat refractory acute GVHD. Blood 109 (10), 4119\u20134126 (2007). PubMed PMID: 17234737. Pubmed Central PMCID: 1885485.","journal-title":"Blood"},{"issue":"7","key":"58936_CR3","doi-asserted-by":"publisher","first-page":"e0271979","DOI":"10.1371\/journal.pone.0271979","volume":"17","author":"MY Zhang","year":"2022","unstructured":"Zhang, M. Y., Zhao, P., Zhang, Y. & Wang, J. S. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. PLoS One. 17 (7), e0271979 (2022). PubMed PMID: 35905125. Pubmed Central PMCID: 9337651.","journal-title":"PLoS One"},{"issue":"9","key":"58936_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.medcli.2016.11.033","volume":"148","author":"JA Guadix","year":"2017","unstructured":"Guadix, J. A., Zugaza, J. L. & Galvez-Martin, P. Characteristics, applications and prospects of mesenchymal stem cells in cell therapy. Med. Clin. (Barc). 148 (9), 408\u2013414 (2017). PubMed PMID: 28126234. Epub 2017\/01\/28. Caracteristicas, aplicaciones y perspectivas de las celulas madre mesenquimales en terapia celular. eng spa.","journal-title":"Med. Clin. (Barc)"},{"issue":"2","key":"58936_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nrm3049","volume":"12","author":"C Nombela-Arrieta","year":"2011","unstructured":"Nombela-Arrieta, C., Ritz, J. & Silberstein, L. E. The elusive nature and function of mesenchymal stem cells. Nat. Rev. Mol. Cell. Biol. 12 (2), 126\u2013131 (2011). PubMed PMID: 21253000. Pubmed Central PMCID: 3346289. Epub 2011\/01\/22. eng.","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"58936_CR6","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3389\/fimmu.2019.02663","volume":"10","author":"MO Gomzikova","year":"2019","unstructured":"Gomzikova, M. O., James, V. & Rizvanov, A. A. Therapeutic Application of Mesenchymal Stem Cells Derived Extracellular Vesicles for Immunomodulation. Front. Immunol. 10, 2663 (2019). PubMed PMID: 31849929. Pubmed Central PMCID: PMC6889906. Epub 2019\/11\/15. eng.","journal-title":"Front. Immunol."},{"issue":"1","key":"58936_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13287-016-0363-7","volume":"7","author":"JL Spees","year":"2016","unstructured":"Spees, J. L., Lee, R. H. & Gregory, C. A. Mechanisms of mesenchymal stem\/stromal cell function. Stem Cell. Res. Ther. 7 (1), 125 (2016). PubMed PMID: 27581859. Pubmed Central PMCID: 5007684. Epub 2016\/09\/02. Eng.","journal-title":"Stem Cell. Res. Ther."},{"issue":"5","key":"58936_CR8","first-page":"267","volume":"4","author":"AJ Friedenstein","year":"1976","unstructured":"Friedenstein, A. J., Gorskaja, J. F. & Kulagina, N. N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4 (5), 267\u2013274 (1976). PubMed PMID: 976387. eng.","journal-title":"Exp. Hematol."},{"issue":"2","key":"58936_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","volume":"14","author":"M Mendicino","year":"2014","unstructured":"Mendicino, M., Bailey, A. M., Wonnacott, K., Puri, R. K. & Bauer, S. R. MSC-based product characterization for clinical trials: an FDA perspective. Cell. Stem Cell. 14 (2), 141\u2013145 (2014). PubMed PMID: 24506881. eng.","journal-title":"Cell. Stem Cell."},{"issue":"4","key":"58936_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/med.21659","volume":"40","author":"J L\u00f3pez-Beas","year":"2020","unstructured":"L\u00f3pez-Beas, J. et al. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. Med. Res. Rev. 40 (4), 1315\u20131334 (2020).","journal-title":"Med. Res. Rev."},{"issue":"9419","key":"58936_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (9419), 1439\u20131441 (2004).","journal-title":"Lancet"},{"key":"58936_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fimmu.2016.00500","volume":"7","author":"M Reis","year":"2016","unstructured":"Reis, M. et al. Recent Developments in Cellular Immunotherapy for HPCT-Associated Complications. Front. Immunol. 7, 500 (2016). PubMed PMID: 27895644. Pubmed Central PMCID: 5107577. Epub 2016\/11\/30. eng.","journal-title":"Front. Immunol."},{"key":"58936_CR13","doi-asserted-by":"publisher","first-page":"105060","DOI":"10.1016\/j.ebiom.2024.105060","volume":"102","author":"A Bayes-Genis","year":"2024","unstructured":"Bayes-Genis, A. et al. Implantation of a double allogeneic human engineered tissue graft on damaged heart: insights from the PERISCOPE phase I clinical trial. EBioMedicine 102, 105060 (2024).","journal-title":"EBioMedicine"},{"issue":"14","key":"58936_CR14","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/cells11142153","volume":"11","author":"J Vives","year":"2022","unstructured":"Vives, J. et al. Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton\u2019s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance. Cells 11(14), 2153. (2022).","journal-title":"Cells"},{"issue":"1","key":"58936_CR15","first-page":"19","volume":"36","author":"M Ramallo","year":"2021","unstructured":"Ramallo, M. et al. Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord. Histol. Histopathol. 36 (1), 19\u201330 (2021). PubMed PMID: 32914860.","journal-title":"Histol. Histopathol"},{"issue":"9","key":"58936_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/pharmaceutics13091336","volume":"13","author":"N Munoz-Dominguez","year":"2021","unstructured":"Munoz-Dominguez, N., Roura, S., Prat-Vidal, C. & Vives, J. Wharton\u2019s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View. Pharmaceutics 13 (9), 1336 (2021).","journal-title":"Pharmaceutics"},{"issue":"2","key":"58936_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2020.08.008","volume":"23","author":"S Albu","year":"2021","unstructured":"Albu, S. et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy 23 (2), 146\u2013156 (2021). PubMed PMID: 32981857.","journal-title":"Cytotherapy"},{"key":"58936_CR18","doi-asserted-by":"publisher","first-page":"102729","DOI":"10.1016\/j.ebiom.2020.102729","volume":"54","author":"C Prat-Vidal","year":"2020","unstructured":"Prat-Vidal, C. et al. First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. EBioMedicine 54, 102729 (2020). PubMed PMID: 32304998. Pubmed Central PMCID: 7163319.","journal-title":"EBioMedicine"},{"issue":"1","key":"58936_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13287-019-1450-3","volume":"10","author":"R Cabrera-Perez","year":"2019","unstructured":"Cabrera-Perez, R. et al. Osteogenic commitment of Wharton\u2019s jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application. Stem Cell. Res. Ther. 10 (1), 356 (2019). PubMed PMID: 31779673. Pubmed Central PMCID: 6883559.","journal-title":"Stem Cell. Res. Ther."},{"issue":"7","key":"58936_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/sctm.16-0492","volume":"6","author":"JE Davies","year":"2017","unstructured":"Davies, J. E., Walker, J. T., Keating, A., Concise & Review Wharton\u2019s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cells Transl Med. 6 (7), 1620\u20131630 (2017). PubMed PMID: 28488282. Pubmed Central PMCID: 5689772.","journal-title":"Stem Cells Transl Med."},{"issue":"1","key":"58936_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.retram.2019.09.001","volume":"68","author":"LL Liau","year":"2020","unstructured":"Liau, L. L., Ruszymah, B. H. I., Ng, M. H. & Law, J. X. Characteristics and clinical applications of Wharton\u2019s jelly-derived mesenchymal stromal cells. Curr. Res. translational Med. 68 (1), 5\u201316 (2020). PubMed PMID: 31543433.","journal-title":"Curr. Res. translational Med."},{"issue":"12","key":"58936_CR22","doi-asserted-by":"publisher","first-page":"9230","DOI":"10.1002\/jcp.29810","volume":"235","author":"H Abbaszadeh","year":"2020","unstructured":"Abbaszadeh, H. et al. Regenerative potential of Wharton\u2019s jelly-derived mesenchymal stem cells: A new horizon of stem cell therapy. J. Cell. Physiol. 235 (12), 9230\u20139240 (2020). PubMed PMID: 32557631.","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"58936_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcyt.2015.10.001","volume":"18","author":"I Oliver-Vila","year":"2016","unstructured":"Oliver-Vila, I. et al. Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton\u2019s jelly. Cytotherapy 18 (1), 25\u201335 (2016). PubMed PMID: 26549383.","journal-title":"Cytotherapy"},{"issue":"1","key":"58936_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-3083.2003.01176.x","volume":"57","author":"K Le Blanc","year":"2003","unstructured":"Le Blanc, K., Tammik, L., Sundberg, B., Haynesworth, S. E. & Ringden, O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57 (1), 11\u201320 (2003). PubMed PMID: 12542793.","journal-title":"Scand. J. Immunol."},{"issue":"7","key":"58936_CR25","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41409-020-0822-8","volume":"55","author":"J Vives","year":"2020","unstructured":"Vives, J., Casademont-Roca, A., Martorell, L. & Nogues, N. Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. Bone Marrow Transpl. 55 (7), 1229\u20131239 (2020). PubMed PMID: 32024991.","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"58936_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","volume":"7","author":"Y Han","year":"2022","unstructured":"Han, Y. et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal. Transduct. Target. Therapy. 7 (1), 92 (2022).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"5","key":"58936_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2796.2007.01844.x","volume":"262","author":"K Le Blanc","year":"2007","unstructured":"Le Blanc, K. & Ringd\u00e9n, O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262 (5), 509\u2013525 (2007). PubMed PMID: 17949362. Epub 2007\/10\/24. eng.","journal-title":"J. Intern. Med."},{"issue":"9624","key":"58936_CR28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (9624), 1579\u20131586 (2008).","journal-title":"Lancet"},{"issue":"1","key":"58936_CR29","first-page":"CD009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher, S. A. et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HPCT) recipients with a haematological condition. Cochrane Database Syst. Rev. 1 (1), CD009768 (2019). PubMed PMID: 30697701. Pubmed Central PMCID: 6353308 translational research from the Leukemia and Lymphoma Research charity and the NIHR.","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"58936_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13287-020-01592-z","volume":"11","author":"C Morata-Tarifa","year":"2020","unstructured":"Morata-Tarifa, C., Macias-Sanchez, M. D. M., Gutierrez-Pizarraya, A. & Sanchez-Pernaute, R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell. Res. Ther. 11 (1), 64 (2020). PubMed PMID: 32070420. Pubmed Central PMCID: 7027118.","journal-title":"Stem Cell. Res. Ther."},{"key":"58936_CR31","doi-asserted-by":"publisher","first-page":"102944","DOI":"10.1016\/j.critrevonc.2020.102944","volume":"150","author":"X Lv","year":"2020","unstructured":"Lv, X. et al. Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis. Crit. Rev. Oncol. Hematol. 150, 102944 (2020). PubMed PMID: 32247246.","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"58936_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/stcltm\/szac003","volume":"11","author":"MDM Macias-Sanchez","year":"2022","unstructured":"Macias-Sanchez, M. D. M. et al. Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience. Stem Cells Transl Med. 11 (4), 343\u2013355 (2022). PubMed PMID: 35348788. Pubmed Central PMCID: 9052408.","journal-title":"Stem Cells Transl Med."},{"issue":"7","key":"58936_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","volume":"53","author":"P Bader","year":"2018","unstructured":"Bader, P. et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 53 (7), 852\u2013862 (2018).","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"58936_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13287-021-02170-7","volume":"12","author":"R Li","year":"2021","unstructured":"Li, R. et al. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis. Stem Cell. Res. Ther. 12 (1), 106 (2021). PubMed PMID: 33541414. Pubmed Central PMCID: 7860635.","journal-title":"Stem Cell. Res. Ther."},{"issue":"1","key":"58936_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13287-019-1287-9","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao, L., Chen, S., Yang, P., Cao, H. & Li, L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell. Res. Ther. 10 (1), 182 (2019). PubMed PMID: 31227011. Pubmed Central PMCID: 6588914.","journal-title":"Stem Cell. Res. Ther."},{"issue":"1","key":"58936_CR36","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","volume":"3","author":"S Hashmi","year":"2016","unstructured":"Hashmi, S. et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 3 (1), e45\u201352 (2016). PubMed PMID: 26765648.","journal-title":"Lancet Haematol."},{"issue":"5","key":"58936_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12026-023-09385-1","volume":"71","author":"S Torrents","year":"2023","unstructured":"Torrents, S. et al. Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use. Immunol. Res. 71 (5), 725\u2013734 (2023). PubMed PMID: 37120479. Pubmed Central PMCID: 10148700.","journal-title":"Immunol. Res."},{"issue":"1","key":"58936_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris, A. C. et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol. Blood Marrow Transpl. 22 (1), 4\u201310 (2016). PubMed PMID: 26386318. Pubmed Central PMCID: 4706482.","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"3","key":"58936_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H. et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol. Blood Marrow Transpl. 21 (3), 389\u2013401 (2015). e1. PubMed PMID: 25529383. Pubmed Central PMCID: 4329079.","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"7","key":"58936_CR40","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J","volume":"60","author":"SB Lansky","year":"1987","unstructured":"Lansky, S. B., List, M. A., Lansky, L. L., Ritter-Sterr, C. & Miller, D. R. The measurement of performance in childhood cancer patients. Cancer 60 (7), 1651\u20131656 (1987). PubMed PMID: 3621134.","journal-title":"Cancer"},{"key":"58936_CR41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","volume":"1","author":"DA Karnofsky","year":"1948","unstructured":"Karnofsky, D. A., Abelmann, W. H., Craver, L. F. & Burchenal, J. H. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1, 634\u2013656 (1948).","journal-title":"Cancer"},{"issue":"9","key":"58936_CR42","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W","volume":"53","author":"V Mor","year":"1984","unstructured":"Mor, V., Laliberte, L., Morris, J. N. & Wiemann, M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53 (9), 2002\u20132007 (1984). PubMed PMID: 6704925. Epub 1984\/05\/01. eng.","journal-title":"Cancer"},{"issue":"3","key":"58936_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10616-021-00474-3","volume":"73","author":"E Garcia-Munoz","year":"2021","unstructured":"Garcia-Munoz, E. & Vives, J. Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology 73 (3), 513\u2013522 (2021). PubMed PMID: 33994662. Pubmed Central PMCID: 8109215.","journal-title":"Cytotechnology"},{"issue":"5","key":"58936_CR44","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/cells8050484","volume":"8","author":"M Grau-Vorster","year":"2019","unstructured":"Grau-Vorster, M. et al. Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton\u2019s Jelly. Cells 8 (5), 484 (2019).","journal-title":"Cells"},{"issue":"1","key":"58936_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10616-017-0186-0","volume":"70","author":"I Oliver-Vila","year":"2018","unstructured":"Oliver-Vila, I. et al. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology 70 (1), 31\u201344 (2018). PubMed PMID: 29322348. Pubmed Central PMCID: 5809679.","journal-title":"Cytotechnology"},{"issue":"10","key":"58936_CR46","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","volume":"20","author":"F Sanchez-Guijo","year":"2014","unstructured":"Sanchez-Guijo, F. et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol. Blood Marrow Transpl. 20 (10), 1580\u20131585 (2014). PubMed PMID: 24952358.","journal-title":"Biol. Blood Marrow Transpl."},{"key":"58936_CR47","doi-asserted-by":"publisher","first-page":"1375493","DOI":"10.3389\/fped.2024.1375493","volume":"12","author":"M Perez-Torres Lobato","year":"2024","unstructured":"Perez-Torres Lobato, M. et al. Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience. Front. Pead. 12, 1375493 (2024). PubMed PMID: 38783918. Pubmed Central PMCID: 11112085.","journal-title":"Front. Pead."},{"issue":"1","key":"58936_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10616-017-0186-0","volume":"70","author":"I Oliver-Vila","year":"2018","unstructured":"Oliver-Vila, I. et al. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells. Cytotechnology 70 (1), 31\u201344 (2018). PubMed PMID: 29322348. Pubmed Central PMCID: PMC5809679. Epub 2018\/01\/10. eng.","journal-title":"Cytotechnology"},{"key":"58936_CR49","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M. & Kr\u00f6ger, N. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. In: (Eds. Carreras, E., Dufour, C., Mohty, M., Kr\u00f6ger, N.). (Cham CH: 2019).","DOI":"10.1007\/978-3-030-02278-5"},{"key":"58936_CR50","unstructured":"Agency, E. M. ICH guideline Q8 (R2) on pharmaceutical development. London (2017)."},{"issue":"3","key":"58936_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrd3052","volume":"9","author":"CK Schneider","year":"2010","unstructured":"Schneider, C. K. et al. Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9 (3), 195\u2013201 (2010). PubMed PMID: 20190786. eng.","journal-title":"Nat. Rev. Drug Discov"},{"key":"58936_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-031-30040-0_3","volume-title":"Potency Assays for Advanced Stem Cell Therapy Medicinal Products","author":"S Torrents","year":"2023","unstructured":"Torrents, S., Grau-Vorster, M. & Vives, J. Potency Assays: The \u2018Bugaboo\u2019 of Stem Cell Therapy. In: (ed Burns, J. S.) Potency Assays for Advanced Stem Cell Therapy Medicinal Products. Cham: Springer International Publishing; 29\u201338. (2023)."},{"issue":"5","key":"58936_CR53","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1087057117696795","volume":"22","author":"Y Fang","year":"2017","unstructured":"Fang, Y. & Eglen, R. M. Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discov. 22 (5), 456\u2013472 (2017). PubMed PMID: 28520521. Pubmed Central PMCID: PMC5448717. eng.","journal-title":"SLAS Discov"},{"issue":"30","key":"58936_CR54","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6 (30), eaba6884 (2020). PubMed PMID: 32832666. Pubmed Central PMCID: 7439491.","journal-title":"Sci. Adv."},{"issue":"416","key":"58936_CR55","doi-asserted-by":"publisher","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","volume":"9","author":"A Galleu","year":"2017","unstructured":"Galleu, A. et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl Med. 9 (416), eaam7828 (2017).","journal-title":"Sci. Transl Med."},{"issue":"4","key":"58936_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/sctm.17-0167","volume":"7","author":"O Ringden","year":"2018","unstructured":"Ringden, O. et al. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. Stem Cells Transl Med. 7 (4), 325\u2013331 (2018). PubMed PMID: 29533533. Pubmed Central PMCID: PMC5866941. Epub 2018\/03\/14. eng.","journal-title":"Stem Cells Transl Med."},{"issue":"3","key":"58936_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjh.17700","volume":"195","author":"S Abedin","year":"2021","unstructured":"Abedin, S. et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Br. J. Haematol. 195 (3), 429\u2013432 (2021). PubMed PMID: 34254289. Pubmed Central PMCID: 9293486.","journal-title":"Br. J. Haematol."},{"issue":"1","key":"58936_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12967-023-04731-1","volume":"21","author":"H Bonig","year":"2023","unstructured":"Bonig, H. et al. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. J. Transl Med. 21 (1), 837 (2023). PubMed PMID: 37990219. Pubmed Central PMCID: 10664468.","journal-title":"J. Transl Med."},{"issue":"12","key":"58936_CR59","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1358\/dot.2012.48.12.1885866","volume":"48","author":"A Daly","year":"2012","unstructured":"Daly, A. & Remestemcel -L, the first cellular therapy product for the treatment of graft-versus-host disease. Drugs Today (Barc). 48 (12), 773\u2013783 (2012). PubMed PMID: 23243634. eng.","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"58936_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2024.10.008","volume":"27","author":"L Renesme","year":"2025","unstructured":"Renesme, L. et al. Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell\u2013based therapeutics. Cytotherapy 27 (2), 146\u2013168 (2025).","journal-title":"Cytotherapy"},{"issue":"2","key":"58936_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","volume":"18","author":"J Galipeau","year":"2016","unstructured":"Galipeau, J. et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18 (2), 151\u2013159 (2016). PubMed PMID: 26724220. Pubmed Central PMCID: PMC4745114. Epub 2015\/12\/23. eng.","journal-title":"Cytotherapy"},{"issue":"7","key":"58936_CR62","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jcyt.2017.03.076","volume":"19","author":"C de Wolf","year":"2017","unstructured":"de Wolf, C., van de Bovenkamp, M. & Hoefnagel, M. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 19 (7), 784\u2013797 (2017). PubMed PMID: 28457740. Epub 2017\/05\/02. eng.","journal-title":"Cytotherapy"},{"issue":"7","key":"58936_CR63","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","volume":"15","author":"P Kebriaei","year":"2009","unstructured":"Kebriaei, P. et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transpl. 15 (7), 804\u2013811 (2009). PubMed PMID: 19539211.","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"6","key":"58936_CR64","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Sensebe, L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell. Stem Cell. 22 (6), 824\u2013833 (2018). PubMed PMID: 29859173. Epub 2018\/06\/03. eng.","journal-title":"Cell. Stem Cell."},{"key":"58936_CR65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-1-4939-7428-3_18","volume":"1698","author":"NWA McGowan","year":"2018","unstructured":"McGowan, N. W. A., Campbell, J. D. M. & Mountford, J. C. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products. Methods Mol. Biol. 1698, 285\u2013292 (2018). PubMed PMID: 29076098. eng.","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"58936_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","volume":"33","author":"C Wrzesinski","year":"2010","unstructured":"Wrzesinski, C. et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33 (1), 1\u20137 (2010). PubMed PMID: 19952961. Pubmed Central PMCID: PMC3247626. Epub 2009\/12\/03. eng.","journal-title":"J. Immunother"},{"issue":"2","key":"58936_CR67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2007.11.014","volume":"2","author":"G Ren","year":"2008","unstructured":"Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell. Stem Cell. 2 (2), 141\u2013150 (2008). PubMed PMID: 18371435. Epub 2008\/03\/29. eng.","journal-title":"Cell. Stem Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58936-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:01:45Z","timestamp":1792591305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58936-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58936-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article omitted an affiliation for S\u00edlvia Torrents. The article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki, local legislation and approved by the Vall d\u00b4Hebron Hospital\u2019s Clinical Research Ethics Committee (reference No. PR(BST)449\/2020, entitled \u201cDerivaci\u00f3 i caracteritzaci\u00f3 exhaustiva de c\u00e8l\u00b7lules mare mesenquimals humanes derivades de cord\u00f3 umbilical\u201d approved on 09\/09\/2024). Written informed consent for participation in this study was provided by the participants\u2019 legal guardians and\/or next of kin. Either the legal tutors or the same patients signed the informed consent to receive compassionate use MSC, WJ-based therapy. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28531"}}